

Application of wearables for remote monitoring of oncology patients: A scoping review

DIGITAL HEALTH
Volume 10: 1–24
© The Author(s) 2024
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/20552076241233998
journals.sagepub.com/home/dhj



Katharina Cloß¹ , Marlo Verket¹, Dirk Müller-Wieland¹, Nikolaus Marx¹, Katharina Schuett¹, Edgar Jost^{2,3}, Martina Crysandt^{2,3}, Fabian Beier^{2,3}, Tim H Brümmendorf^{2,3}, Guido Kobbe^{3,4}, Julia Brandts^{1,5} and Malte Jacobsen¹

Abstract

Objective: This review aims to systematically map and categorize the current state of wearable applications among oncology patients and to identify determinants impeding clinical implementation.

Methods: A Medline, Embase and clinicaltrials.gov search identified journal articles, conference abstracts, letters, reports, dissertations and registered studies on the use of wearables in patients with malignancies published up to 10 November 2021.

Results: Of 2509 records identified, 112 met the eligibility criteria. Of these, 9.8% (11/112) were RCTs and 47.3% (53/112) of publications were observational. Wearables were investigated pre-treatment (2.7%; 3/112), during treatment (34.8%; 39/112), post-treatment (17.9%; 20/112), in survivors (27.7%; 31/112) and in non-specified or multiple treatment phases (17.0%; 19/112). Medical-grade wearables were applied in 22.3% (25/112) of publications. Primary objectives ranged from technical feasibility (8.0%; 9/112), user feasibility (42.9%; 48/112) and correlational analysis (40.2%; 45/112) to outcome change analysis (8.9%; 10/112). Outcome change was mostly investigated regarding physical activity improvement (80.0%; 8/10). Most publications (42.9%; 48/112) and registered studies (39.3%; 24/61) featured multiple cancer types, with breast cancer as the most prevalent specific type (22.3% in publications, 16.4% in registered studies).

Conclusions: Most studies among oncology patients using wearables are focused on assessing the user feasibility of consumer-grade wearables, whereas rates of RCTs assessing clinical efficacy are low. Substantial improvements in clinically relevant endpoints by the use of wearables, such as morbidity and mortality are yet to be demonstrated.

Keywords

Wearables, oncology, remote patient monitoring, cancer, digital health

¹Department of Internal Medicine I, Medical Faculty, RWTH Aachen University, Aachen, Germany

²Department of Internal Medicine IV, Medical Faculty, RWTH Aachen University, Aachen, Germany

³Center for Integrated Oncology, Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen, Germany

⁴Department of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany

⁵Imperial Centre for Cardiovascular Disease Prevention (ICCP), Department of Primary Care and Public Health, School of Public Health, Imperial College London, London, UK

Julia Brandts and Malte Jacobsen shared last authorship.

Corresponding author:

Malte Jacobsen, Department of Internal Medicine I, Medical Faculty, RWTH Aachen University, University Hospital Aachen, Pauwelsstraße 30, 52074 Aachen, Germany.

Email: mjacobsen@ukaachen.de



Creative Commons NonCommercial-NoDerivs CC BY-NC-ND: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 License (<https://creativecommons.org/licenses/by-nc-nd/4.0/>) which permits any use, reproduction and distribution of the work as published without adaptation or alteration, provided the original work is attributed as specified on the SAGE and Open Access page (<https://us.sagepub.com/en-us/nam/open-access-at-sage>).

Introduction

An aging population with increasing cancer prevalence poses significant challenges to healthcare systems worldwide.¹ Personalized pre-treatment assessment becomes paramount due to diverse treatment options, including CAR-T cell therapy. During cancer treatment, patients may encounter complications like infections, frailty, cardiac disorders and treatment-specific side effects, for example, cytokine release syndrome.^{2–4} Decreased physical activity (PA), fatigue syndrome and mental health disorders are commonly observed during follow-up of cancer patients.^{5,6} Early detection of health deterioration could reduce rates of hospitalization or emergency visits, as shown in other medical fields.^{7–9} Moreover, delayed diagnosis and treatment of complications are associated with higher morbidity and mortality.¹⁰ As outpatient treatment becomes more prevalent, disease monitoring largely depends on patient self-management and regular clinic visits, posing challenges to patients and healthcare professionals (HCP) and underscoring the need for effective monitoring techniques.¹⁰

Wearable devices equipped with non-invasive sensors offer continuous health data monitoring under daily life conditions. These “wearables” utilize well-established sensor technologies, such as accelerometry, temperature probes and photoplethysmography, enabling subsequent or real-time data acquisition. Generating and processing vast amounts of “big data” is challenging yet offers vast opportunities in healthcare. It enables the creation of a “digital twin”—a virtual patient representation that helps anticipate clinical events and guide personalized treatment decisions by monitoring changes in real-time parameter.¹¹

Wearables have been successfully applied to early detect COVID-19,¹² heart failure,¹³ Alzheimer’s disease¹⁴ and seizures in patients with epilepsy,¹⁵ as well as health deterioration or adverse events (AE) of certain therapies.¹⁶ Additionally, wearables can objectify patient-reported outcomes (PRO), otherwise prone to subjectivity and highly depend on patient adherence, such as quality of life (QoL)¹⁷ and pain.¹⁸ Furthermore, wearables can serve as interventional tools to enhance PA,^{19–23} thereby improving overall well-being.^{20,23}

Despite their potential across diverse applications, wearables are rarely implemented clinically in oncology. This scoping review aims to explore the current state of wearable application among oncology patients, focusing on determinants impeding clinical implementation by evaluating and extracting information from published clinical studies.

Methods

For this scoping review, the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA-ScR) were used.²⁴ The final protocol was registered with the

Open Science Framework on 16 November 2021 (<https://osf.io/bgmya>).²⁵

We included publications focusing on wearable application in adult patients with a confirmed oncologic disease. The term “wearable” is defined as a mobile hardware device with integrated software that collects clinical data via non-invasive sensors by measuring different parameters. Medline, Embase and clinicaltrials.gov were searched up to 10 November 2021 for full-text journal articles, letters, reports, dissertations, conference abstracts and trial registrations in any language (with keywords in English) with no limitation in the date of publication. The search strategies employed are described in Supplemental Tables 1 and 2. Keywords for the search on clinicaltrials.gov were “wearable” and “oncology.”

Three authors (KC, MV and MJ) independently assessed the eligibility of records through title and abstract screening, followed by full-text screening. Disagreements were settled by a fourth author (JB) through consensus. Data extraction was performed by the first author (KC) and revised by a second author (MJ or MV), using a standardized form (Supplemental Table 3).

For quality assessment, full-text records’ adherence to research guidelines was evaluated using aspects of STROBE, CONSORT and TREND, which we merged into a shorter checklist (Supplemental Table 4). A three-point grading system was used to categorize guideline adherence as “full,” “partly” or “none.” Due to a heterogeneous nomenclature of study designs, publications were categorized according to the common nomenclature of study designs.²⁶ Study objectives were categorized by stage of maturity, modified after the World Health Organization “Monitoring and Evaluating Digital Health Interventions” manual to reflect the stages a wearable passes through from prototype to clinical implementation.²⁶ Collected parameters were categorized to warrant a coherent data analysis. A full list of categories with specifications is presented in Supplemental Table 5. In the case of study characteristics with more than one feature option (e.g. malignancy type, wearable type) reported shares might not add up to 100%. Registered planned studies from clinicaltrials.gov are presented as future perspectives.

Results

The literature search yielded a total of 2509 publications, with 112 publications meeting eligibility criteria after title, abstract and full-text screening (Figure 1). Main characteristics of included publications are listed in Table 1.

An increasing number of published studies can be observed from the earliest eligible publication in 2007 until 2021 (26 publications) with a short-lasting decrease in 2020 (14 studies) (Figure 2). Most studies were published by first authors located in the USA (55.4%; 62/112), followed by Europe (29.5%; 33/112), Asia (6.3%; 7/112), Canada and Australia (both 4.5%; 5/112) (Supplemental Figure 4).




Figure 1. PRISMA flow diagram of the screening and selection of publications.

The search of clinicaltrials.gov resulted in 117 registrations, of which 61 were eligible. 63.9% (39/61) of those were registered by researchers located in the USA (Supplemental Figure 5).

Study characteristics

Study characteristics are summarized in Table 2. Around 10% of publications were RCTs and nearly half of publications applied a prospective longitudinal design (47.3%; 53/112) followed by 19.6% (22/112) cross-sectional studies.

Only 8.9% (10/112) of publications conducted outcome change analyses (Figure 3), applying a weighted mean duration of 80.2 days (47.8–112.7).

Interestingly, compared to this, the share of registered RCTs is four times higher. The share of registered outcome change analysis is three times higher compared to publications, applying a higher planned average duration of 129.1 days.

Device characteristics

Device characteristics are shown in Table 2. 22.3% (25/112) of publications applied medical-grade devices.

Within the subset of EU-based publications, 27.8% (5/18) incorporated medical-grade devices, while in USA-based publications, medical-grade devices were used in 17.7% (11/62) of publications.

The most commonly used sensors were accelerometers and actigraphs (85.7%; 96/112), followed by HR sensors (16.1%; 18/112), temperature sensors (3.6%; 4/112) and ECG (1.8%; 2/112). In 76.8% (86/112) of publications, one sensor was applied, 21.4% (24/112) utilized two to four sensors and 1.8% (2/112) did not specify applied sensors.

Registered studies do not show a clear trend to applying multiple sensors: 65.6% (40/61) of registered studies are planning to employ one sensor, followed by two sensors (18.0%; 11/61), five sensors (1.6%; 1/61) or not specified sensor count (9.9%; 9/91).

Participants' characteristics

Participants' characteristics are reported in Table 2. Included populations had a weighted mean age of 50.1 (48.2–51.9) years and a mean female participant ratio of 51.5%, or 45.2%, excluding studies assessing a sex-specific malignancy. Most publications (42.9%) and registered

Table 1. Main characteristics of included publications; n = 112.

Study ID	Number of participants (n)	Trial duration (days)	Study design (classified)	Treatment phase	Primary objective	Malignancy	Wearable detected parameters (classified)
Alberts et al. ⁵⁷	65	30	RCT	Survivor	User feasibility	Non-specific	Vital signs
Andraos et al. ³⁰	38	Not specified	Cross-sectional	During	Correlation of wearable data to clinical outcome	Non-specific	PA
Bade et al. ⁸¹	39	7	Cross-sectional	Non-specific	User feasibility	Lung	PA
Blair et al. ⁸²	54	91	RCT	Survivor	User feasibility	Non-specific	PA; sedentary behavior
Carter et al. ⁸³	29	90	Secondary analysis	Survivor	Technical feasibility	Breast	Vital signs
Cereda et al. ⁸⁴	10	27	Prospective longitudinal	During	Technical feasibility	Myelogenous leukemia	Energy expenditure
Cos et al. ³⁴	48	28	Prospective longitudinal	Prior	Correlation of wearable data to clinical outcome	Pancreas	PA; vital signs; sleep
Courneya et al. ⁸⁵	500	Not specified	Prospective longitudinal	Survivor	User feasibility	Breast	PA; sedentary behavior; energy expenditure; posture
Dadhania et al. ⁸⁶	42	82	Prospective longitudinal	During	User feasibility	Glioma	PA
Dambrosio et al. ⁸⁷	10	Not specified	Prospective longitudinal	During	User feasibility	Leukemia	Vital Signs
Dambrosio et al. ³¹	17	Not specified	Prospective longitudinal	During	Correlation of wearable data to clinical outcome	Leukemia	Vital signs
De Cocker et al. ⁸⁸	9	7	Cross-sectional	Survivor	User feasibility	Breast	PA
Dorion et al. ⁸⁹	12	9	Prospective longitudinal	During	Correlation of wearable data to clinical outcome	Non-specific	PA
Dreher et al. ⁹⁰	65	270	Prospective longitudinal	During	User feasibility	Breast	PA

(continued)

Table 1. Continued.

Study ID	Number of participants (n)	Trial duration (days)	Study design (classified)	Treatment phase	Primary objective	Malignancy	Wearable detected parameters (classified)
Ferrante et al. ⁹¹	35	180	RCT	Survivor	User feasibility	Breast	PA
Ferrante et al. ⁴³	36	180	RCT	Survivor	Outcome change	Breast	PA
Ferrante et al. ⁹²	44	360	Secondary analysis	Survivor	User feasibility	Breast	PA
Ferriolli et al. ³³	182	7	Prospective longitudinal	During	Correlation of wearable data to clinical outcome	Non-specific	PA; sedentary behavior; gait
Fink et al. ⁹³	not specified	Not specified	Prospective longitudinal	During	Correlation of wearable data to clinical outcome	Non-specific	ECG
Fischer et al. ⁹⁴	20	7	Secondary analysis	Non-specific	User feasibility	Non-specific	PA; sleep
Flora et al. ⁹⁵	62	8.5	Prospective longitudinal	During	Correlation of wearable data to clinical outcome	Non-specific	vital signs
Frensham et al. ⁹⁶	8	42	Quasi-experimental	Survivor	User feasibility	Non-specific	PA
Furtado et al. ⁹⁷	34	7	Cross-sectional	Post	User feasibility	Sarcoma	Gait
Gallicchio et al. ⁹⁸	20	2.5	Prospective longitudinal	Post	Technical feasibility	Thyroid	PA; vital signs; radiation
Gell et al. ⁹⁹	19	28	Quasi-experimental	Survivor	User feasibility	Non-specific	PA
Ghods et al. ¹⁰⁰	40	21	Prospective longitudinal	Non-specific	Correlation of wearable data to clinical outcome	Gastrointestinal	PA
Gresham et al. ¹⁰¹	37	14	Prospective longitudinal	Non-specific	Correlation of wearable data to clinical outcome	Non-specific	PA
Groarke et al. ¹⁰²	102	56	Secondary analysis	Survivor	User feasibility	Non-specific	PA
Gupta et al. ¹⁰³	24	84	Cross-sectional	During	User feasibility	Non-specific	PA; sleep; sedentary behavior
Hardcastle et al. ¹⁰⁴	68	84	Secondary analysis	Survivor	User feasibility	Non-specific	PA

(continued)

Table 1. Continued.

Study ID	Number of participants (n)	Trial duration (days)	Study design (classified)	Treatment phase	Primary objective	Malignancy	Wearable detected parameters (classified)
Hartman et al. ¹⁰⁵	42	84	Secondary analysis	Non-specific	User feasibility	Breast	PA; sedentary behavior
Hasan Shandhi et al. ²⁹	12	Not specified	Prospective longitudinal	Non-specific	User feasibility	Breast	ECG; left ventricular function
Helbrich et al. ¹⁰⁶	99	28	Prospective longitudinal	During	Correlation of wearable data to pro	Breast	PA
Hevroni et al. ³⁸	40	Not specified	Prospective longitudinal	During	Correlation of wearable data to pro	Multiple myeloma	Sleep
Holden et al. ¹⁰⁷	80	8	Prospective longitudinal	During	User feasibility	Colorectal	PA
Hoogland et al. ¹⁰⁸	45	3	Prospective longitudinal	Prior	Correlation of wearable data to pro	Hematologic	PA; sleep
Innominato et al. ³²	77	3	Secondary analysis	During	Correlation of wearable data to clinical outcome	Colorectal	PA; sleep
Innominato et al. ¹⁰⁹	31	58	Prospective longitudinal	During	Correlation of wearable data to clinical outcome	Non-specific	PA; sleep
Innominato et al. ¹⁷	268	3	Secondary analysis	During	Correlation of wearable data to pro	Non-specific	PA; sleep
Ip et al. ¹¹⁰	10	22	Quasi-experimental	During	User feasibility	NHL/ multiple myeloma	PA; vital signs
Izmailova et al. ¹¹¹	188	Not specified	Prospective longitudinal	During	Correlation of wearable data to clinical outcome	Non-specific	PA
Izmailova et al. ¹¹²	66	Not specified	Prospective longitudinal	During	Correlation of wearable data to clinical outcome	Head/ neck	PA
Jakobsen et al. ³⁹	40	1	Cross-sectional	Non-specific	Correlation of wearable data to pro	Non-specific	sleep

(continued)

Table 1. Continued.

Study ID	Number of participants (n)	Trial duration (days)	Study design (classified)	Treatment phase	Primary objective	Malignancy	Wearable detected parameters (classified)
Jeffery et al. ¹¹³	46	7	Cross-sectional	Non-specific	User feasibility	Malignant pleural effusion	PA; sedentary behavior
Jonker et al. ¹¹⁴	24	90	Prospective longitudinal	Post	User feasibility	Non-specific	PA
Jonker et al. ¹¹⁵	47	90	Prospective longitudinal	Post	User feasibility	Non-specific	PA
Jovanovic et al. ¹¹⁶	38	Not specified	Secondary analysis	Survivor	Correlation of wearable data to pro	Endometrial	PA
Jurdi et al. ⁴¹	63	13	Prospective longitudinal	During	Correlation of wearable data to clinical outcome	Hematologic	PA; vital signs; sleep
Kerr et al. ⁶⁰	30	7	Cross-sectional	Survivor	Technical feasibility	Breast	PA
Khetrapal et al. ¹¹⁷	30	7	Cross-sectional	During	User feasibility	Bladder	PA
Kim et al. ⁵⁸	44	140	Prospective longitudinal	During	Correlation of wearable data to clinical outcome	Thyroid	Vital signs
Kim et al. ¹¹⁸	40	Not specified	Prospective longitudinal	During	Correlation of wearable data to pro	Gastrointestinal	PA; vital signs
Komarzynski et al. ¹¹⁹	31	30	Prospective longitudinal	During	Correlation of wearable data to pro	Non-specific	Sleep
Kong et al. ⁴⁷	152	7	RCT	During	Outcome change	Breast	PA; energy expenditure
Koontz et al. ⁵⁶	30	90	Quasi-experimental	Survivor	User feasibility	Non-specific	PA
Korde et al. ³⁷	40	Not specified	Prospective longitudinal	During	Correlation of wearable data to pro	Multiple myeloma	PA; sleep
Laccetti et al. ¹²⁰	15	182	Prospective longitudinal	During	User feasibility	Prostate	PA; vital signs

(continued)

Table 1. Continued.

Study ID	Number of participants (n)	Trial duration (days)	Study design (classified)	Treatment phase	Primary objective	Malignancy	Wearable detected parameters (classified)
LeBaron et al. ¹²¹	not specified	Not specified	Cross-sectional	Non-specific	User feasibility	Non-specific	PA; vital signs
Lee et al. ⁴⁸	100	84	RCT	Post	Outcome change	Prostate	PA
Lemanska et al. ⁶⁹	116	180	Quasi-experimental	Survivor	Outcome change	Prostate	PA
Liu et al. ¹²²	86	3	Prospective longitudinal	During	Correlation of wearable data to pro	Breast	sleep
Low et al. ³⁵	14	38	Cross-sectional	During	Correlation of wearable data to pro	Gastrointestinal	PA; sleep; sedentary behavior
Low et al. ⁵⁰	71	12	Prospective longitudinal	Post	Correlation of wearable data to clinical outcome	Peritoneal	PA
Low et al. ¹²³	24	28	Cross-sectional	During	Correlation of wearable data to pro	Gastrointestinal	PA
Low et al. ¹²⁴	44	81	Prospective longitudinal	During	Correlation of wearable data to pro	Pancreas	PA; vital signs; sleep
Lozano-Lozano et al. ¹²⁵	80	56	Quasi-experimental	Survivor	User feasibility	Breast	PA; sedentary behavior
Lynch et al. ⁶⁸	83	84	RCT	Survivor	Outcome change	Breast	PA; sleep; sedentary behavior
Maddocks et al. ¹²⁶	60	6	Prospective longitudinal	Non-specific	User feasibility	Non-specific	PA; sedentary behavior; energy expenditure
Martin et al. ¹²⁷	24	180	Secondary analysis	Survivor	User feasibility	Breast	PA
Miropolsky et al. ¹²⁸	13	Not specified	Quasi-experimental	Survivor	User feasibility	Non-specific	PA
Nguyen et al. ¹²⁹	14	14	Cross-sectional	Survivor	User feasibility	Breast	PA; sedentary behavior
Nyrop et al. ⁴⁴	100	84	Prospective longitudinal	During	User feasibility	Breast	PA

(continued)

Table 1. Continued.

Study ID	Number of participants (n)	Trial duration (days)	Study design (classified)	Treatment phase	Primary objective	Malignancy	Wearable detected parameters (classified)
O'Connor et al. ⁴⁰	30	3	Prospective longitudinal	Non-specific	Correlation of wearable data to pro	Non-specific	Sleep
Ohri et al. ¹³⁰	38	70	Prospective longitudinal	During	Correlation of wearable data to clinical outcome	Non-specific	PA
Otte et al. ¹³¹	55	7	Prospective longitudinal	Survivor	Technical feasibility	Breast	Sleep
Palla et al. ⁵²	54	5	Quasi-experimental	Post	Correlation of wearable data to clinical outcome	Non-specific	Not specified
Pavic et al. ¹³²	30	84	Prospective longitudinal	Post	User feasibility	Non-specific	PA; vital signs
Pavic et al. ¹³³	31	84	Prospective longitudinal	Post	User feasibility	Non-specific	PA; vital signs; gait
Peterson et al. ¹³⁴	137	10	Cross-sectional	Non-specific	User feasibility	Non-specific	PA; vital signs
Peterson et al. ¹³⁵	357	Not specified	Prospective longitudinal	During	Correlation of wearable data to pro	Head/ neck	HR; vital signs
Pfister et al. ¹³⁶	266	7	Cross-sectional	Post	Technical feasibility	Breast	PA; sedentary behavior
Quintiliani et al. ¹³⁷	10	70	Prospective longitudinal	Survivor	User feasibility	Breast	PA
Rosenberg et al. ⁵⁹	26	21	Prospective longitudinal	Post	User feasibility	Prostate	PA; sedentary behavior
Rossi et al. ¹³⁸	25	30	Cross-sectional	Survivor	User feasibility	Endometrial	PA
Sada et al. ⁵³	28	2	Secondary analysis	Post	Correlation of wearable data to PRO	Non-Specific	PA; sleep; sedentary behavior; posture; balance
Schuler et al. ¹³⁹	20	28	Secondary analysis	During	User feasibility	Non-specific	PA

(continued)

Table 1. Continued.

Study ID	Number of participants (n)	Trial duration (days)	Study design (classified)	Treatment phase	Primary objective	Malignancy	Wearable detected parameters (classified)
Skender et al. ²⁷	198	10	Cross-sectional	Non-specific	Technical feasibility	Colorectal	PA
Sugiyama et al. ¹⁴⁰	21	39	Prospective longitudinal	During	Correlation of wearable data to pro	Urothel	PA; vital signs; sleep; energy expenditure
Skipworth et al. ¹⁴¹	45	14	Cross-sectional	Non-specific	Technical feasibility	Non-specific	PA
Slade et al. ¹⁴²	20	30	Prospective longitudinal	Post	User feasibility	Bladder	PA; vital signs; sleep
Strother et al. ⁴⁵	33	36	RCT	Post	Outcome change	Bladder	PA
Sun et al. ³⁶	20	27	Prospective longitudinal	Post	Correlation of wearable data to clinical outcome	Non-specific	PA
Timmerman et al. ⁵⁴	17	Not specified	Cross-sectional	Survivor	User feasibility	Lung	PA; vital signs
Tipps et al. ¹⁴³	not specified	365	Prospective longitudinal	Non-specific	Correlation of wearable data to pro	Glioblastoma	PA; sleep
Torrente et al. ¹⁴⁴	112	7	Cross-sectional	Non-specific	Correlation of wearable data to pro	Lung	PA; vital signs; radiation
Tramontano et al. ¹⁴⁵	not specified	Not specified	Prospective longitudinal	During	Correlation of wearable data to pro	Non-specific	PA; vital signs
Trinh et al. ¹⁴⁶	46	84	Quasi-experimental	Survivor	User feasibility	Prostate/ urothel	PA; sedentary behavior
Uhm et al. ⁴⁹	356	84	Quasi-experimental	Post	Outcome change	Breast	PA
Ungar et al. ¹⁴⁷	67	28	Quasi-experimental	Non-specific	Outcome change	Non-specific	PA
Vallance et al. ¹⁴⁸	180	7	Cross-sectional	Survivor	Correlation of wearable data to pro	Colon	PA; sedentary behavior
Valle et al. ⁵⁵	35	180	RCT	Survivor	Outcome change	Breast	PA

(continued)

Table 1. Continued.

Study ID	Number of participants (n)	Trial duration (days)	Study design (classified)	Treatment phase	Primary objective	Malignancy	Wearable detected parameters (classified)
Van Blarigan et al. ¹⁴⁹	41	84	RCT	Survivor	User feasibility	Colorectal	PA; energy expenditure
Verma et al. ¹⁵⁰	86	7	Prospective longitudinal	Post	Correlation of wearable data to clinical outcome	Hematologic	Vital signs
Waliany et al. ¹⁵¹	25	10	Prospective longitudinal	During	Technical feasibility	Breast	Energy expenditure
Waller et al. ⁴⁶	22	Not specified	RCT	Prior	Outcome change	Colorectal	PA
Ward et al. ¹⁵²	80	4	Prospective longitudinal	Post	User feasibility	Colorectal	PA
Wong et al. ¹⁵³	26	Not specified	Prospective longitudinal	Non-specific	Correlation of wearable data to clinical outcome	Non-specific	PA; energy expenditure
Wright et al. ¹⁵⁴	10	30	Quasi-experimental	Post	User feasibility	Non-specific	PA; vital signs
Wu et al. ⁵¹	43	28	Prospective longitudinal	Post	Correlation of wearable data to clinical outcome	Gastric	PA
Wu et al. ¹⁵⁵	10	362	Secondary analysis	Non-specific	Correlation of wearable data to clinical outcome	Non-specific	PA
Xu et al. ⁴²	91	88	Quasi-experimental	Survivor	Outcome change	Breast	PA; vital signs
Zahiri et al. ¹⁵⁶	139	Not specified	Cross-sectional	Survivor	Correlation of wearable data to clinical outcome	Non-specific	Gait; posture




Figure 2. Number of published studies (year 2007–2021) and registered studies on clinicaltrials.gov (year >2021) per treatment phase per year of publication.

studies (39.3%) featured multiple cancer types, with breast cancer as the prevalent specific type (22.3% in publications, 16.4% in registered studies).

Primary objectives

Figure 3 depicts the primary study objectives of publications according to the maturity stage of the assessed wearable.

Technical feasibility. 8.0% (9/112) of publications assessed the accuracy, reliability, or validation of wearables, for example, minimum number of nights needed to obtain accurate results of objective sleep²⁹ or association of wearable and pedometer measurements.²⁷

User feasibility. Most publications (42.9%; 48/112) examined user feasibility, for example, by assessing wearable usage, trial completion, data transmission or adverse events. This heterogeneity of feasibility definition is described in detail by other reviewers.²⁸ A single study described wearable applications as “potentially feasible,”²⁹ and all remaining studies concluded a high level of feasibility.

The share of feasibility assessment as the primary objective will be exceeded by registered studies (50.1%; 31/61).

Correlational analysis. Correlational analyses of wearable data to clinical outcomes and to PRO were conducted by 40.2% (45/112) of publications. Wearable data were demonstrated to correlate to hospitalization rate,³⁰ AE,³¹ overall survival,³² performance,³³ risk,³⁴ symptoms^{35,36} and QoL.³⁷ However, consistent correlations of wearable data to subjectively reported PA or sleep were not established due to inaccurate sleep tracking and misinterpretation of inactivity as sleep by wearables.^{38–40} Similarly, according to the authors, a correlation between activity and hospitalization duration could not be demonstrated consistently due to variations in the study population.⁴¹

Fewer registered studies plan to conduct correlational analyses (19.7%; 12/61), resembling clinical endpoints of published studies. One novel approach is a correlational analysis of wearable data and pain.

Outcome change analysis. A small share of publications analyzed outcome change (8.9%; 10/112), predominantly aiming to improve PA as the primary endpoint (80%; 8/10). Two publications measured weight loss as a primary endpoint (20%; 2/10).^{42,43} A beneficial effect of wearables was mainly apparent among patients characterized as post-treatment and cancer survivors. Two publications report a lack of positive outcomes after wearable-supported

Table 2. Main characteristics in publications and registered studies.

		Published studies	Registered studies (clinicaltrials.gov)
Study characteristics			
Number		112	61
Study design	RCT	9.8% (n = 11)	44.3% (n = 27)
	Quasi-experimental	11.6% (n = 13)	11.5% (n = 7)
	Prospective longitudinal	47.3% (n = 53)	32.8% (n = 20)
	Cross-sectional	19.6% (n = 22)	11.5% (n = 7)
	Secondary analyses	11.6% (n = 13)	0% (n = 0)
Mean no. of participants (min – max)		64.4 (8–500)	97.9 (10–528)
Weighted mean study duration (days) (95% CI)		36.6 (25.1–47.5)	-
Planned mean study duration (days) (min – max)		-	124.3 (1 h – 365 days)
Device characteristics			
Device type	Medical-grade	22.3% (n = 25)	11.5% (n = 7)
	Consumer-grade	50.0% (n = 56)	50.8% (n = 31)
	Not specified	34.8% (n = 39)	37.7% (n = 23)
Parameters	PA	80.4% (n = 90)	70.5% (n = 43)
	Vital signs	23.2% (n = 26)	31.1% (n = 19)
	Sleep	15.2% (n = 17)	11.5% (n = 7)
Device company	Fitbit	31.3% (n = 35)	37.7% (n = 23)
	ActiGraph	15.2% (n = 17)	3.3% (n = 2)
	PAL technologies	5.4% (n = 6)	0% (n = 0)
	GARMIN	5.4% (n = 6)	8.2% (n = 5)
Participants' characteristics			
Demographics	Weighted mean age (years) (95% CI)	50.1 (48.2–51.9)	-
	Female ratio (%) (95% CI)	51.5 (45.3–57.7)	-
Malignancy type	Multiple	42.9% (48/112)	39.3% (24/112)

(continued)

Table 2. Continued.

		Published studies	Registered studies (clinicaltrials.gov)
	Breast	22.3% (n = 25)	16.4% (n = 10)
	Hematologic/lymphatic	8.0% (n = 9)	3.3% (n = 2)
	Prostate/Urothel	8.0% (n = 9)	8.2% (n = 5)
	Colorectal	6.3% (n = 7)	3.3% (n = 2)
	Gastrointestinal	4.5% (n = 5)	6.6 (n = 4)
	Lung	2.7% (n = 3)	11.5% (n = 7)
Treatment phase	Pre-treatment	2.7% (n = 3)	6.6% (n = 4)
	During treatment	34.8% (n = 39)	23.0% (n = 14)
	Post-treatment	17.9% (n = 20)	26.2% (n = 16)
	Survivor	27.7% (n = 31)	11.5% (n = 7)
	Not specified/multiple	17.0% (n = 19)	32.8% (n = 20)




Figure 3. Primary study objectives of published studies according to the stage of maturity, modified after “WHO monitoring and evaluating digital health interventions.” The sizes of the boxes do not correspond to the number of studies of the respective category.

interventions, due to a lack of motivation⁴⁴ and underpowered study conditions,⁴⁵ according to the authors.

Registered trials plan to conduct more outcome change analyses (27.9%; 17/61) with a broader variability of clinical endpoints, which will be reported in the respective treatment phases of the following paragraph.

Treatment phases

The distribution of treatment phases in which the studies were conducted is presented in Table 2. Study endpoints

within respective treatment phases and respective stages of maturity are presented in Figure 4.

Pretreatment phase. Of the three publications that assessed patients pre-treatment, two studies were conducted as prospective longitudinal studies and one study was an RCT.⁴⁶ Wearables were reported to be successfully applied for surgical risk assessment³⁴ and as a prehabilitation tool before surgery.⁴⁶

Registered studies show a relative increase in studies utilizing wearables in the pre-treatment phase. Of the

Continuum of oncology care					
	pre treatment	during treatment	post treatment	survivor	non-specific
Maturity	Feasibility (n=1) - surgical risk assessment ¹⁴	(n=10) - PA monitoring ^{95,96,117,120,129,140} - vital sign monitoring ¹¹⁰ - predict toxicities ^{97,107} - objectify assessment ¹⁰³ - increase PA ^{44,147}	(n=9): - PA monitoring ^{95,97,114,115,143,155} - predict toxicities ¹⁵³ , hospitalization ¹³³	(n=21): - PA monitoring ^{95,104} - increase breathing ⁹⁷ , PA ^{155,56,82,88,91,92,96,99,102,125,128,130,138,147,150}	(n=8): - PA monitoring ^{113,135} - objectify QoL ⁸¹ - predict cancer pain ¹²¹ - detect AE ²⁹
	Correlation to clinical outcome	(n=13): - predict hospitalization ^{50,41,106,111,112,131, OS^{92,98}} - early detect AE ^{31,58,93} - objectify performance ⁵⁹	(n=4): - predict hospitalization ^{50,51} - early detect AE ^{52,151}	(n=1): - predict CIPN severity ¹⁵⁷	(n=4): - objectify performance ¹⁰⁰ - predict AE ¹⁵⁴
	Correlation to PRO (n=1) - predict recovery of QoL ¹⁰⁸	(n=13): - objectify symptoms ^{50,119,123,134,141} - QoL ^{17,37,118,122,136,149} - self-reported PA ¹⁴⁶	(n=2): - objectify symptoms and QoL ³⁹ , CRF ⁵³	(n=2): - objectify patient-reported PA ¹¹⁶ - objectify symptoms ¹⁴⁹	(n=4): - objectify QoL ¹⁴⁵ , symptoms ¹⁴⁴
	Outcome change (n=1) - prehabilitation ⁴⁰	(n=1): - increase PA ⁴⁷	(n=3): - increase PA ^{42,8,49}	(n=4): - increase PA ^{44,58,59} - weight loss ^{42,43}	(n=1): - increase PA ¹⁴⁸

Figure 4. Study endpoints within the continuum of oncology care, categorized according to study objectives' stage of maturity (n = 112). The number in brackets represents the number of studies in the respective category. Technical feasibility is not displayed.

three studies that plan to apply wearables for prehabilitation, two will conduct outcome change analysis (NCT03902834, NCT03689634) and one will assess feasibility (NCT03162718).

During treatment phase. Of the 39 publications that assessed patients during treatment, one was designed as RCT, aiming to increase PA⁴⁷ and 26 publications (66.7%) conducted correlational analyses.

Of the 20 registered studies, during treatment, wearables will mainly be applied for feasibility assessment. An exercise intervention for balance improvement by wearable application represents a novel investigational approach in oncology (NCT02773329).

Posttreatment phase. Of the 20 publications which assessed patients post-treatment, one was designed as RCT.⁴⁵ Wearables were reported to be successfully applied to increase PA,^{42,48,49} predict hospitalization^{50,51} and toxicities⁵² and objectify symptoms,⁵³ among others. One study implementing an intervention to increase PA did not show a significant benefit due to underpowered study conditions, according to the authors.⁴⁵

Of the 16 registered studies, wearables post-treatment are planned to be applied to conduct exercise interventions to increase PA mostly, either the latter being the primary endpoint (NCT05046756, NCT05031052, NCT04907591, NCT04783168) or investigating subsequent effects of PA increase, for example, reduced readmissions (NCT04314778), decreased insulin resistance (NCT04649671), improved bone mineral density (NCT04144127) and changes in mental health

(NCT03874754). Further registered studies aim to decrease ultraviolet (UV) exposure (NCT03344796, NCT03518229).

Survivor phase. Of the 31 publications including cancer survivors, 21 conducted feasibility assessments. Seven studies were designed as RCTs, assessing feasibility and outcome change of exercise interventions. Wearables were reported to be successfully applied to increase PA⁵⁴ and to reduce body weight.⁴³

Of the nine registered studies, wearable-based interventions aim to increase PA (NCT03612596) and reduce UV exposure (NCT03927742). Feasibility assessment of a breathing intervention represents a novel approach to wearable application in oncology (NCT03773380).

No specific treatment phase. Of the 19 published studies that did not specify a treatment phase or analyzed cohorts from multiple treatment phases, most studies included cohorts with multiple malignancy types (57.9%; 11/19).

One study of 12 registered studies plans to decrease cardiotoxicity risk by implementing a preventive, artificial intelligence-based intervention in a clinical setting (NCT04885088).

Quality assessment

The full evaluation is given in Supplemental Table 4. The majority of publications eligible for quality assessment did not specify their study design in the title or abstract by using commonly recognized terms (56.3%; 36/64). Eligibility criteria, sources and methods of selection of participants and methods of follow-up were not defined by 31.3% (20/64) of studies.

Study size determination was described in only 12.5% (8/64) of studies. Most studies did not address missing data handling 81.3% (52/64). Number of participants at each stage of the study was not reported by 31.3% (20/64) of studies. Generalizability was not discussed by 70.3% (45/64) of studies. Reasons for limited generalizability were selection bias to patient selection, for example, due to required technical⁵⁵/smartphone access^{56,57} or required smartphone literacy⁵⁸ and small sample size.^{59,60}

Discussion

For this scoping review, 112 research papers, published between 2007 and 2021, were identified that examined wearable applications in oncology, regarding their technical and user feasibility, correlation of wearable data to PRO and to clinical outcomes and their capability to change participants' lifestyles. This study indicates a rising use of wearables addressing variable endpoints in oncology research across the continuum of oncology care.

The surge in studies on wearables in oncology is driven by technological advancements, a focus on patient empowerment and personalized medicine, the potential for cost-effectiveness and early detection and intervention, interdisciplinary collaboration, demand for increasing outpatient treatment and surveillance and growing regulatory interest. This exponential growth of publications on wearable applications has been documented not only in oncology^{28,61–63} but also in other medical fields,^{64,65} for example, chronic diseases.⁶⁶ In oncology, prior reviews assessed wearable devices, but limited their research to specific data items, for example, activity data,⁶² analyzing wearable usage in a certain oncologic treatment phase,²⁸ or investigating particular objectives, for example, adherence and clinical outcomes.^{28,67}

The average age of study participants was ~50 years, with this younger demographic particularly receptive to new technologies. A restricted access to wearable usage due to lack of familiarity with smart devices and technical requirements such as reliable internet connection or the necessity of owning a compatible private smartphone limit generalizability of included studies.^{55–57} Further selection biases discussed by authors of included studies arise due to higher motivation⁶⁸ of study participants, higher educational level⁶⁹ and a healthier lifestyle⁷⁰ compared to the general cancer populations. In order to antagonize digital health disparities, these aspects should be considered while interpreting the results of the respective trials. For real-world implementation, these aspects should be addressed by wearable manufacturers, HCPs and research centers.

Further, the evaluation of the efficacy of wearables on clinical outcomes, a crucial step before clinical implementation, was only conducted sparsely, primarily showing success in survivor cohorts and in posttreatment cohorts. Despite a slight trend toward assessment during and

posttreatment, critical treatment phases require further investigation, addressing clinical endpoints beyond change in PA.

More homogenous participant cohorts, especially concerning a specific cancer type, could add value to research results since physical conditions of patients with different cancer types and treatment modalities often vary. Evidence of wearable application in specific cancer cohorts might facilitate clinical implementation of wearables, since patients are often bound to cancer-specific centers or wards and thus could be elected and approached easily.

The clinical impact on oncology outcomes currently mainly seems favorable to PA improvement, in line with Jo et al., who investigated clinical outcomes of wearable application in patients with chronic diseases.⁶⁶ Successful *long-term* PA improvement and subsequent clinical changes remain to be shown. Only two studies confirmed a significant PA increase after 3 months compared to a control group with no intervention and no wearable.^{46,68} Of those, one was a single-center study with 22 participants, which achieved a significant improvement in the 6 Minutes-Walk-Test. However, a significant change in daily active minutes could not be achieved.⁴⁶ Lynch et al. describe a significant PA increase and sedentary time reduction in breast cancer survivors after three months.⁶⁸ Further studies indicated PA increase or weight loss up to 3 months, but without the comparison to a control group,⁴² or with no significant difference to included control groups.^{42,43,48,49,69} Only two studies present outcome change results after 6 months: Lemanska et al. report a PA decrease after initial PA increase after 3 months (with no control group) and Kong et al. found increased PA levels with no significant difference to a control group without wearable.^{46,69}

In line with an increase in PA, two of the above-mentioned publications observed significant weight loss after 3 months,^{42,43} whereas QoL remained unaltered.⁴² Future studies should address additional clinical endpoints induced by altered PA. Limited change can be observed considering the number of applied sensors in published studies and planned studies. Wearable research in oncology populations is predominantly based on one sensor—both in published and registered studies. Despite these trends, longer study duration and inclusion of well-defined patient populations with respective control groups are desirable. The high share of feasibility analyses of publications and planned studies should proceed to more advanced study objectives. Innovative technology with multi-sensor approaches could enhance wearables' potential in predicting diseases and optimizing treatment selection through the concept of a "digital twin."

A high share of studies published by US-based authors was observed in line with other reviews.^{62,70} Strict regulatory laws concerning medical certification in the EU were presumed as a cause.⁷⁰ This assumption can only be agreed

with regarding prospective medical certification since this review found a high share of studies that applied consumer-grade devices without medical certification—both in the EU and the USA. More strict data privacy and security regulations in the EU complicate research in this sensitive field, both from researchers' and from participants' points of view, who might be skeptical concerning the adaption of new technologies and especially concerning the processing of sensitive personal health data.⁷¹ One-third of the adult US population is estimated to use wearables⁷² and more than 80% of US wearable users report willingness to share wearable information with HCPs.⁷³ In contrast, only 19% of the EU population between 16 and 74 years reported to use wearables in 2020.⁷⁴ Although this information cannot be directly compared, wearable usage is likely more common in the USA than in Europe.

"No evidence, no implementation—no implementation, no evidence"—this paradox stated by Guo et al. encapsulates the challenges of digital health, relating to a lack of real-world evidence of digital health solutions.⁷⁵ Evidence-based evaluation of wearables is crucial for patients, HCPs, investors, regulatory bodies, wearable developers and benefactors. Observational study designs with small sample sizes were prevalent in this scoping review, mainly focusing on feasibility and correlational analyses during cancer treatment and in cancer survivors. Despite low flexibility and long periods from planning to publication and difficulties of blinding, RCTs remain the gold standard for efficacy assessment. Only a small proportion of publications were RCTs, while a higher share of registered studies plans to conduct RCTs, focusing on during and post-treatment evaluations.

Innovative study designs are needed to address the challenges encountered in digital health research, for example, dynamics of digitization, software updates and software bugs. "Pragmatic RCT," adaptive designs and virtual trials are possible approaches to complement conventional RCT.⁷⁶ Alternative study designs such as Continuous Evaluation of Evolving Behavioral Intervention Technologies (CEEBIT), Multiphase Optimization Strategy (MOST), Sequential Multiple Assignment Randomized Trials (SMART), Factorial/Fractional RCT and Micro-Randomized Trials (MRT) are seen as helpful tools for the development of digital health interventions.^{76–78} Various frameworks and guidelines for the evaluation of digital health interventions are reviewed by Kernebeck et al., including, for example, a CONSORT-STROBE expansion for eHealth interventions.⁷⁹

Moreover, our review indicates a need for further efforts to use medical-grade wearables for accurate data collection. The results call for investigations of wearables' short-term and long-term effectiveness in oncology populations, including survival rates, malignancy recurrence rates and hospitalization rates. Wearables' capability to potentially predict symptoms and identify patients' deterioration early may facilitate patient care with malignant diseases

and result in improved clinical outcomes. Besides health outcome changes, positive effects of wearable application on healthcare processes should be demonstrated, for example, in terms of economic or financial evaluation and workload reduction of HCPs.

The strengths and limitations of the present study merit consideration. First, the application of a wearable and measurement of parameters, which can be consciously controlled by the patient (e.g. PA), could be seen as an intervention *per se*, according to the Hawthorne effect.⁸⁰ In this review, studies intending to change collected parameters (e.g. through a step goal) were considered interventional studies and studies which applied wearables to, for example, foresee clinical events, were considered observational studies. Second, the categorization of parameters was conducted carefully, with an attempt to achieve a meaningful and objective evaluation. However, any categorization can lead to a certain bias in the results—especially when analyzing and classifying heterogeneous studies. Furthermore, the categories are partly overlapping and are not as clear in practice as they are in theory, which might lead to restricted reproducibility. Third, technical devices new to the market, such as wearables, are prone to fast-moving development of hardware and software. Since trials often present momentary assessment of devices, technical changes, especially in early published studies, cannot warrant continued validity. This also applies to this scoping review. Fourth, the interpretation of clinicaltrials.gov is limited by the fact that details of the study, such as trial performance, completion and publication, are not reliable. Aimed study designs and methods could be adapted due to altered circumstances and downward adjustment of planned study quality seems more likely than vice versa.

Conclusions

Although less than 10% of clinical evaluations of wearables in oncology patients were done by RCTs so far, wearables appear to show promise for improving clinical care of patients with malignant diseases. Challenges in evidence creation, study design and regulatory aspects need to be addressed for their effective implementation. Long-term outcome change of wearables should be analyzed to demonstrate their effectiveness. Wearable application should be assessed in critical treatment phases, analyzing end-points beyond PA change. Application of medical-grade wearables is desirable, optimally able to process big data sets or even enabling the adaption of algorithms based on the "digital twin" concept.

Acknowledgments: None.

Contributorship: KC contributed to conceptualization, methodology, data curation, formal analysis and writing—original

draft. MV contributed to conceptualization, methodology, data curation and review and editing. DM-W contributed to supervision, conceptualization and review and editing. NM contributed to review and editing. KS contributed to review and editing. EJ contributed to review and editing. MC contributed to review and editing. FB contributed to review and editing. TB contributed to review and editing. GK contributed to review and editing. JB contributed to project administration, conceptualization, methodology, data curation, visualization and review and editing. MJ contributed to project administration, conceptualization, methodology, data curation, visualization and review and editing.

Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethical approval: Not applicable.

Funding: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research received funding from the internal grant program of the University Hospital Aachen, RWTH Aachen University, Germany. Dr Marx is supported by the Deutsche Forschungsgemeinschaft (German Research Foundation; TRR 219; Project-ID 322900939 [M03, M05]).

Guarantor: MJ, JB.

Informed consent: This manuscript presents a literature review of publicly available information. Since no individual data were used for the analysis presented in this manuscript, the requirement for consent is not applicable.

Registration: The review was registered in the Open Science Framework register by first author KC (née Hagenkamp) (<https://osf.io/bgmya>).

ORCID iD: Katharina Cloß  <https://orcid.org/0009-0007-4430-1242>

Supplementary material: Supplemental material for this article is available online.

References

1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2021; 71: 209–249. DOI: 10.3322/caac.21660
2. Varricchi G, Galdiero MR, Marone G, et al. Cardiotoxicity of immune checkpoint inhibitors. *ESMO Open* 2017; 2: e000247. DOI: 10.1136/esmoopen-2017-000247.
3. Guan M, Zhou YP, Sun JL, et al. Adverse events of monoclonal antibodies used for cancer therapy. *Biomed Res Int* 2015; 2015: 428169. DOI: 10.1155/2015/428169.
4. Handforth C, Clegg A, Young C, et al. The prevalence and outcomes of frailty in older cancer patients: a systematic review. *Ann Oncol* 2015; 26: 1091–1101. DOI: 10.1093/annonc/mdl540.
5. Romero SAD, Jones L, Bauml JM, et al. The association between fatigue and pain symptoms and decreased physical activity after cancer. *Support Care Cancer* 2018; 26: 3423–3430. DOI: 10.1007/s00520-018-4203-4.
6. Niedzwiedz CL, Knifton L, Robb KA, et al. Depression and anxiety among people living with and beyond cancer: a growing clinical and research priority. *BMC Cancer* 2019; 19: 20191011. DOI: 10.1186/s12885-019-6181-4.
7. Katsaras T, Milsis A, Rizikari M, et al. The use of the “Healthwear” wearable system in chronic patients’ early hospital discharge, control randomized clinical trial. *Int Symp Med Inf Commun Technol* 2011; 5: 143–146. DOI: 10.1109/ISMICT.2011.5759815.
8. Kwasnicki RM, Ali R, Jordan SJ, et al. A wearable mobility assessment device for total knee replacement: a longitudinal feasibility study. *Int J Surg* 2015; 18: 14–20. DOI: 10.1016/j.ijsu.2015.04.032.
9. Mohamadipanah H, Wise B, Witt A, et al. Performance assessment using sensor technology. *J Surg Oncol* 2021; 124: 200–215. DOI: 10.1002/jso.26519.
10. Hanna TP, King WD, Thibodeau S, et al. Mortality due to cancer treatment delay: systematic review and meta-analysis. *Br Med J* 2020; 371: m4087. DOI: 10.1136/bmj.m4087.
11. Coorey G, Figtree GA, Fletcher DF, et al. The health digital twin to tackle cardiovascular disease—a review of an emerging interdisciplinary field. *NPJ Digit Med* 2022; 5: 126. DOI: 10.1038/s41746-022-00640-7.
12. Cheong SHR, Ng YJX, Lau Y, et al. Wearable technology for early detection of COVID-19: a systematic scoping review. *Prev Med* 2022; 162: 107170. DOI: 10.1016/j.ypmed.2022.107170.
13. Singhal A and Cowie MR. The role of wearables in heart failure. *Curr Heart Fail Rep* 2020; 17: 125–132. DOI: 10.1007/s11897-020-00467-x.
14. Varatharajan R, Manogaran G, Priyan MK, et al. Wearable sensor devices for early detection of Alzheimer disease using dynamic time warping algorithm. *Cluster Comput* 2017; 21: 681–690. DOI: 10.1007/s10586-017-0977-2.
15. Verdu J and Van Paesschen W. Wearable seizure detection devices in refractory epilepsy. *Acta Neurol Belg* 2020; 120: 1271–1281. DOI: 10.1007/s13760-020-01417-z.
16. Breteler MJM, KleinJan E, Numan L, et al. Are current wireless monitoring systems capable of detecting adverse events in high-risk surgical patients? A descriptive study. *Injury* 2020; 51: S97–S105. DOI: 10.1016/j.injury.2019.11.018.
17. Innominato PF, Komarzynski S, Palesh OG, et al. Circadian rest-activity rhythm as an objective biomarker of patient-reported outcomes in patients with advanced cancer. *Cancer Med* 2018; 7: 4396–4405. <https://doi.org/10.1002/cam4.1711>.
18. Johnson A, Yang F, Gollarahalli S, et al. Use of mobile health apps and wearable technology to assess changes and predict pain during treatment of acute pain in sickle cell disease: feasibility study. *JMIR Mhealth Uhealth* 2019; 7: e13671. DOI: 10.2196/13671.

19. Ferguson T, Olds T, Curtis R, et al. Effectiveness of wearable activity trackers to increase physical activity and improve health: a systematic review of systematic reviews and meta-analyses. *Lancet Digit Health* 2022; 4: e615–e626. DOI: 10.1016/S2589-7500(22)00111-X.
20. Singh B, Zopf EM and Howden EJ. Effect and feasibility of wearable physical activity trackers and pedometers for increasing physical activity and improving health outcomes in cancer survivors: a systematic review and meta-analysis. *J Sport Health Sci* 2022; 11: 184–193. DOI: 10.1016/j.jshs.2021.07.008.
21. Brickwood KJ, Watson G, O'Brien J, et al. Consumer-based wearable activity trackers increase physical activity participation: systematic review and meta-analysis. *JMIR mHealth uHealth* 2019; 7: e11819. DOI: 10.2196/11819.
22. Franssen WMA, Franssen G, Spaas J, et al. Can consumer wearable activity tracker-based interventions improve physical activity and cardiometabolic health in patients with chronic diseases? A systematic review and meta-analysis of randomised controlled trials. *Int J Behav Nutr Phys Act* 2020; 17: 57. DOI: 10.1186/s12966-020-00955-2.
23. Zahrt OH, Evans K, Murnane E, et al. Effects of wearable fitness trackers and activity adequacy mindsets on affect, behavior, and health: longitudinal randomized controlled trial. *J Med Internet Res* 2023; 25: e40529. DOI: 10.2196/40529.
24. Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. *Ann Intern Med* 2018; 169: 467–473. DOI: 10.7326/M18-0850.
25. Hagenkamp K and Jacobsen M. Application of wearable sensors for remote monitoring of oncology patients: a scoping review, <https://doi.org/10.17605/OSF.IO/BGMYA> (2021).
26. World Health Organization. *Monitoring and evaluating digital health interventions: a practical guide to conducting research and assessment*. Geneva: WHO, 2016.
27. Skender S, Schrotz-King P, Bohm J, et al. Repeat physical activity measurement by accelerometry among colorectal cancer patients—feasibility and minimal number of days of monitoring. *BMC Res Notes* 2015; 8: 222. DOI: 10.1186/s13104-015-1168-y.
28. Beauchamp UL, Pappot H and Hollander-Mieritz C. The use of wearables in clinical trials during cancer treatment: systematic review. *JMIR mHealth uHealth* 2020; 8: e22006. <https://doi.org/10.2196/22006>.
29. Hasan Shandhi MM, Aras M, Wynn S, et al. Cardiac function monitoring for patients undergoing cancer treatments using wearable seismocardiography: a proof-of-concept study. *Conf Proc IEEE Eng Med Biol Soc* 2020; 2020: 4075–4078. DOI: 10.1109/EMBC44109.2020.9176074.
30. Andraos TY, Asaro AM, Garg MK, et al. Real-time activity monitoring to prevent admissions during radiotherapy (RAMPART). *Int J Radiat Oncol Biol Phys* 2019; 105: E463. DOI: 10.1016/j.ijrobp.2019.06.1424.
31. Dambrosio N, Porter M, Bauer E, et al. Identifying neutropenic fever earlier: an application of a skin patch for continuous temperature monitoring. *Blood* 2018; 132: 4718. DOI: 10.1182/blood-2018-99-114181.
32. Innominato PF, Giacchetti S, Bjarnason GA, et al. Prediction of overall survival through circadian rest-activity monitoring during chemotherapy for metastatic colorectal cancer. *Int J Cancer* 2012; 131: 2684–2692. <https://doi.org/10.1002/ijc.27574>.
33. Ferriolli E, Skipworth RJE, Hendry P, et al. Physical activity monitoring: a responsive and meaningful patient-centered outcome for surgery, chemotherapy, or radiotherapy? *J Pain Symptom Manage* 2012; 43: 1025–1035. <https://doi.org/10.1016/j.jpainsymman.2011.06.013>.
34. Cos H, Li D, Williams G, et al. Predicting outcomes in patients undergoing pancreatotomy using wearable technology and machine learning: prospective cohort study. *JMIR* 2021; 23: e23595. <https://doi.org/10.2196/23595>.
35. Low CA, Dey AK, Ferreira D, et al. Estimation of symptom severity during chemotherapy from passively sensed data: exploratory study. *JMIR* 2017; 19: e420. <https://doi.org/10.2196/jmir.9046>.
36. Sun V, Dumitra S, Ruel N, et al. Wireless monitoring program of patient-centered outcomes and recovery before and after major abdominal cancer surgery. *JAMA surg* 2017; 152: 852–859. <https://doi.org/10.1001/jamasurg.2017.1519>.
37. Korde N, Tavitian E, Derkach A, et al. Association of patient activity bioprofiles with Hrql and clinical responses: a prospective novel trial using mobile wearables in newly diagnosed multiple myeloma patients. *Blood* 2020; 136: 26–28. DOI: 10.1182/blood-2020-142082.
38. Hevroni G, Mastey D, Tavitian E, et al. Using mobile wearables to establish sleep bioprofiles in newly diagnosed multiple myeloma (MM) patients. *JCO* 2021; 39: 15. DOI: 10.1200/JCO.2021.39.15_suppl.8040.
39. Jakobsen G, Engstrom M, Thronaes M, et al. Sleep quality in hospitalized patients with advanced cancer: an observational study using self-reports of sleep and actigraphy. *Supportive Care Cancer* 2020; 28: 2015–2023. <https://doi.org/10.1007/s00520-019-04998-5>.
40. O'Connor B, Uí Dhuibhir P, Higgins S, et al. Cancer-related insomnia: wireless monitoring of sleep metrics in advanced disease. *BMJ Support Palliat Care* 2017; 7: A1. DOI: 10.1136/bmjspcare-2017-00133.2.
41. Jurdi NE, Nock N, Fu P, et al. Physical activity and sleep measures using a fitness tracking device during hematopoietic cell transplantation: a pilot study. *Transplant Cell Ther* 2021; 27: 502.e501–502.e506. <https://doi.org/10.1016/j.jctct.2021.02.015>.
42. Xu L, Zhou C, Ling Y, et al. Effects of short-term unsupervised exercise, based on smart bracelet monitoring, on body composition in patients recovering from breast cancer. *Integr Cancer Ther* 2021; 20: 15347354211040780. <https://doi.org/10.1177/15347354211040780>.
43. Ferrante JM, Doose M, Bator A, et al. Virtual weight loss program for African-American breast cancer survivors: preliminary results. *JCO* 2017; 35: 163. DOI: 10.1200/JCO.2017.35.5_suppl.163.
44. Nyrop KA, Deal AM, Choi SK, et al. Measuring and understanding adherence in a home-based exercise intervention during chemotherapy for early breast cancer. *Breast Cancer Res Treat* 2018; 168: 43–55. <https://doi.org/10.1007/s10549-017-4565-1>.

45. Strother M, Koepsell K, Song L, et al. Financial incentives and wearable activity monitors to increase ambulation after cystectomy: a randomized controlled trial. *Urol Oncol* 2021; 39: 434.e431–434.e438. <https://doi.org/10.1016/j.urolonc.2020.11.035>.
46. Waller E, Rahman S, Sutton P, et al. Randomised controlled trial of patients undergoing prehabilitation with wearables versus standard of care before major abdominal cancer surgery. *Colorectal Dis* 2020; 22: 7. DOI: 10.1111/codi.15168.
47. Kong S, Lee JK, Kang D, et al. Comparing the effectiveness of a wearable activity tracker in addition to counseling and counseling only to reinforce leisure-time physical activity among breast cancer patients: a randomized controlled trial. *Cancers (Basel)* 2021; 13: 2692. DOI: 10.3390/cancers13112692.
48. Lee BJ, Park YH, Lee JY, et al. Smartphone application versus pedometer to promote physical activity in prostate cancer patients. *Telemed J E Health* 2019; 25: 1231–1236. <https://doi.org/10.1089/tmj.2018.0233>.
49. Uhm KE, Yoo JS, Chung SH, et al. Effects of exercise intervention in breast cancer patients: is mobile health (mHealth) with pedometer more effective than conventional program using brochure? *Breast Cancer Res Treat* 2017; 161: 443–452. <https://doi.org/10.1007/s10549-016-4065-8>.
50. Low CA, Bovbjerg DH, Ahrendt S, et al. Fitbit step counts during inpatient recovery from cancer surgery as a predictor of readmission. *Ann Behav Med* 2018; 52: 88–92. <https://doi.org/10.1093/abm/kax022>.
51. Wu J-M, Ho T-W, Chang Y-T, et al. Wearable-based mobile health app in gastric cancer patients for postoperative physical activity monitoring: focus group study. *JMIR mHealth UHealth* 2019; 7: e11989. <https://doi.org/10.2196/11989>.
52. Palla I, Lorenzoni V, D'Isidoro C, et al. A new organizational integrated home-care model: an Italian pilot study. *Value Health* 2016; 19: A747–A748.
53. Sada YH, Poursina O, Zhou H, et al. Harnessing digital health to objectively assess cancer-related fatigue: the impact of fatigue on mobility performance. *PloS one* 2021; 16: e0246101. <https://doi.org/10.1371/journal.pone.0246101>.
54. Timmerman JG, Tonis TM, Dekker-van Weering MGH, et al. Co-creation of an ICT-supported cancer rehabilitation application for resected lung cancer survivors: design and evaluation. *BMC Health Serv Res* 2016; 16: 155. <https://doi.org/10.1186/s12913-016-1385-7>.
55. Valle CG, Deal AM and Tate DF. Preventing weight gain in African American breast cancer survivors using smart scales and activity trackers: a randomized controlled pilot study. *J Cancer Surviv* 2017; 11: 133–148. <https://doi.org/10.1007/s11764-016-0571-2>.
56. Koontz BF, Levine E, McSherry F, et al. Increasing physical activity in cancer survivors through a text-messaging exercise motivation program (ICanSTEP). *Supportive Care Cancer* 2021; 29: 7339–7349. <https://doi.org/10.1007/s00520-021-06281-y>.
57. Alberts NM, Leisenring WM, Flynn JS, et al. Wearable respiratory monitoring and feedback for chronic pain in adult survivors of childhood cancer: a feasibility randomized controlled trial from the childhood cancer survivor study. *JCO Clin Cancer Inform* 2020; 4: 1014–1026. <https://doi.org/10.1200/CCI.20.00070>.
58. Kim K-H, Lee J, Ahn CH, et al. Association between thyroid function and heart rate monitored by wearable devices in patients with hypothyroidism. *Endocrinol Metab* 2021; 36: 1121–1130. DOI: 10.3803/EnM.2021.1216.
59. Rosenberg D, Kadokura EA, Bouldin ED, et al. Acceptability of Fitbit for physical activity tracking within clinical care among men with prostate cancer. AMIA Annual Symposium proceedings AMIA Symposium 2016; 2016: 1050-1059.
60. Kerr J, Carlson J, Godbole S, et al. Improving hip-worn accelerometer estimates of sitting using machine learning methods. *Med Sci Sports Exerc* 2018; 50: 1518–1524. DOI: 10.1249/MSS.0000000000001578.
61. Magalhaes B, Fernandes C, Santos C, et al. The use of mobile applications for managing care processes during chemotherapy treatments: a systematic review. *Cancer Nurs* 2021; 44: E339–E360. <https://doi.org/10.1097/NCC.0000000000000823>.
62. Gresham G, Schrack J, Gresham LM, et al. Wearable activity monitors in oncology trials: current use of an emerging technology. *Contemp Clin Trials* 2018; 64: 13–21. DOI: 10.1016/j.cct.2017.11.002.
63. Huang Y-W, Wu C-S, Chuang C-K, et al. Real-time and label-free detection of the prostate-specific antigen in human serum by a polycrystalline silicon nanowire field-effect transistor biosensor. *Anal Chem* 2013; 85: 7912–7918. <https://doi.org/10.1021/ac401610.s>.
64. Cudejko T, Button K, Willott J, et al. Applications of wearable technology in a real-life setting in people with knee osteoarthritis: a systematic scoping review. *J Clin Med* 2021; 10: 20211130. DOI: 10.3390/jcm10235645.
65. Wells CI, Xu W, Penfold JA, et al. Wearable devices to monitor recovery after abdominal surgery: scoping review. *BJS Open* 2022; 6: 31. DOI: 10.1093/bjsopen/zrac031.
66. Jo A, Coronel BD, Coakes CE, et al. Is there a benefit to patients using wearable devices such as fitbit or health apps on mobiles? A systematic review. *Am J Med* 2019; 132: 1394–1400 e1391. DOI: 10.1016/j.amjmed.2019.06.018.
67. Huang Y, Upadhyay U, Dhar E, et al. A scoping review to assess adherence to and clinical outcomes of wearable devices in the cancer population. *Cancers (Basel)* 2022; 14: 20220913. DOI: 10.3390/cancers14184437.
68. Lynch BM, Nguyen NH, Moore MM, et al. A randomized controlled trial of a wearable technology-based intervention for increasing moderate to vigorous physical activity and reducing sedentary behavior in breast cancer survivors: the ACTIVATE trial. *Cancer* 2019; 125: 2846–2855. <https://doi.org/10.1002/cncr.32143>.
69. Lemanska A, Poole K, Griffin B, et al. Community pharmacy: an innovative way to deliver cancer survivorship interventions. *Support Care Cancer* 2019; 27: S94–S95. DOI: 10.1007/s00520-019-04813-1.
70. Huhn S, Axt M, Gunga HC, et al. The impact of wearable technologies in health research: scoping review. *JMIR Mhealth Uhealth* 2022; 10: e34384. DOI: 10.2196/34384.
71. What is GDPR, the EU's new data protection law?, <https://gdpr.eu/what-is-gdpr/> (accessed 26 July 2023).

72. Dhingra LS, Aminorroaya A, Oikonomou EK, et al. Use of wearable devices in individuals with or at risk for cardiovascular disease in the US, 2019 to 2020. *JAMA Netw Open* 2023; 6: e2316634. DOI: 10.1001/jamanetworkopen.2023.16634.
73. Rising CJ, Gaysynsky A, Blake KD, et al. Willingness to share data from wearable health and activity trackers: analysis of the 2019 health information national trends survey data. *JMIR Mhealth Uhealth* 2021; 9: e29190. DOI: 10.2196/29190.
74. Statistisches Bundesamt. Pressemitteilung Nr. 078 vom 22 Februar 2021, https://www.destatis.de/DE/Presse/Pressemitteilungen/2021/02/PD21_078_639.html (2021, accessed 28 August 2023).
75. Guo C, Ashrafian H, Ghafur S, et al. Challenges for the evaluation of digital health solutions-A call for innovative evidence generation approaches. *NPJ Digit Med* 2020; 3: 110. DOI: 10.1038/s41746-020-00314-2.
76. Hemkens LG. [Benefit assessment of digital health applications-challenges and opportunities]. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz* 2021; 64: 1269–1277. DOI: 10.1007/s00103-021-03413-x.
77. Gensorowsky D, Lampe D, Hasemann L, et al. “Alternative study designs” for the evaluation of digital health applications - a real alternative? *Z Evid Fortbild Qual Gesundheitswes* 2021; 161: 33–41. DOI: 10.1016/j.zefq.2021.01.006.
78. Hrynyschyn R, Prediger C, Stock C, et al. Evaluation methods applied to digital health interventions: what is being used beyond randomised controlled trials?-A scoping review. *Int J Environ Res Public Health* 2022; 19: 20220425. DOI: 10.3390/ijerph19095221.
79. Kernebeck S, Kramer U, Redaelli M, et al. Bewerten, aber wie? – Kriterien für die evaluation und das reporting von Studien zu Gesundheits- und Medizin-apps. *Monitor Versorgungsforschung* 2021; 14: 69–75. DOI: 10.24945/mvf.02.21.1866-0533.2300.
80. Schwartz D, Fischhoff B, Krishnamurti T, et al. The Hawthorne effect and energy awareness. *Proc Natl Acad Sci U S A* 2013; 110: 15242–15246. DOI: 10.1073/pnas.1301687110.
81. Bade BC, Brooks MC, Nietert SB, et al. Assessing the correlation between physical activity and quality of life in advanced lung cancer. *Integr Cancer Ther* 2018; 17: 73–79. <https://doi.org/10.1177/1534735416684016>.
82. Blair CK, Harding E, Wiggins C, et al. A home-based mobile health intervention to replace sedentary time with light physical activity in older cancer survivors: randomized controlled pilot trial. *JMIR Cancer* 2021; 7: e18819. <https://doi.org/10.2196/18819>.
83. Carter SJ, Rogers LQ, Bowles HR, et al. Inverse association between changes in energetic cost of walking and vertical accelerations in non-metastatic breast cancer survivors. *Eur J Appl Physiol* 2019; 119: 2457–2464. DOI: 10.1007/s00421-019-04227-1.
84. Cereda E, Turrini M, Ciapanna D, et al. Assessing energy expenditure in cancer patients: a pilot validation of a new wearable device. *JPEN* 2007; 31: 502–507.
85. Courneya KS, McNeely ML, Culos-Reed SN, et al. The Alberta moving beyond breast cancer (AMBER) cohort study: recruitment, baseline assessment, and description of the first 500 participants. *BMC Cancer* 2016; 16: 481. <https://doi.org/10.1186/s12885-016-2534-4>.
86. Dadhania S, Pakzad-Shahabi L, Mistry S, et al. Brainwear: longitudinal, objective assessment of physical activity in 42 HGG patients. *Neuro Oncol* 2021; 23: ii13. DOI: 10.1093/neuonc/noab180.043.
87. Dambrosio N, Gannon J, Eager J, et al. Feasibility of monitoring of body temperature for patients undergoing stem cell transplant or intensive chemotherapy. *JCO* 2017; 35: 15. DOI: 10.1200/JCO.2017.35.15_suppl.e21630.
88. De Cocker K, Charlier C, Van Hoof E, et al. Development and usability of a computer-tailored pedometer-based physical activity advice for breast cancer survivors. *Eur J Cancer Care* 2015; 24: 673–682. <https://doi.org/10.1111/ecc.12225>.
89. Dorion V, Lambert L, Frazzi A, et al. A pilot study in the use of activity trackers for assessing response to palliative radiotherapy. *Cureus* 2017; 9: e1871. <https://doi.org/10.7759/cureus.1871>.
90. Dreher N, Haderer EK, Hartman SJ, et al. Fitbit usage in patients with breast cancer undergoing chemotherapy. *Clin Breast Cancer* 2019; 19: 443–449.e441. <https://doi.org/10.1016/j.clbc.2019.05.005>.
91. Ferrante JM, Devine KA, Bator A, et al. Feasibility and potential efficacy of commercial mHealth/eHealth tools for weight loss in African American breast cancer survivors: pilot randomized controlled trial. *Transl Behav Med* 2018; 10: 938–948. DOI: 10.1093/tbm/iby124.
92. Ferrante JM, Lulla A, Williamson JD, et al. Patterns of fitbit use and activity levels among African American breast cancer survivors during an eHealth weight loss randomized controlled trial. *Am J Health Promot* 2022; 36: 94–105. DOI: 10.1177/08901171211036700.
93. Fink LS, Schinkoethe T, Wuerstlein R, et al. Substantial ninety-nine percent reduction of turnaround time for QTc diagnostics using smartphone-based telecardiology. *JCO* 2020; 38: 15. DOI: 10.1200/JCO.2020.38.15_suppl.e14155.
94. Fischer I, Horneber M, Falge C, et al. Actigraphy and ecological momentary assessment of fatigue in cancer outpatients. *Onkologie* 2010; 33: 179–180. DOI: 10.1159/000321410.
95. Flora C, Tyler J, Mayer C, et al. High-frequency temperature monitoring for early detection of febrile adverse events in patients with cancer. *Cancer Cell* 2021; 39: 1167–1168. DOI: 10.1016/j.ccell.2021.07.019.
96. Frensham LJ, Zarnowiecki DM, Parfitt G, et al. The experiences of participants in an innovative online resource designed to increase regular walking among rural cancer survivors: a qualitative pilot feasibility study. *Supportive Care Cancer* 2014; 22: 1923–1929. <https://doi.org/10.1007/s00520-014-2177-4>.
97. Furtado S, Godfrey A, Del Din S, et al. Are accelerometer-based functional outcome assessments feasible and valid after treatment for lower extremity sarcomas? *Clin Orthop Relat Res* 2019; 478: 482–503. <https://doi.org/10.1097/CORR.0000000000000883>.
98. Gallicchio R, Scapicchio D, Nardelli A, et al. Assessment of residual radioactivity by a comprehensive wireless, wearable device in thyroid cancer patients undergoing radionuclide therapy and comparison with the results of a home

- device: a feasibility study. *IEEE J Transl Eng Health Med* 2021; 9: 2700306. <https://doi.org/10.1109/JTEHM.2020.3042118>.
99. Gell NM, Tursi A, Grover KW, et al. Female cancer survivor perspectives on remote intervention components to support physical activity maintenance. *Supportive Care Cancer* 2019; 28: 2185–2194. <https://doi.org/10.1007/s00520-019-05038-y>.
 100. Ghods A, Shahrokni A, Ghasemzadeh H, et al. Remote monitoring of the performance status and burden of symptoms of patients with gastrointestinal cancer via a consumer-based activity tracker: quantitative cohort study. *JMIR Cancer* 2021; 7: e22931. DOI: 10.2196/22931.
 101. Gresham G, Hendifar AE, Spiegel B, et al. Wearable activity monitors to assess performance status and predict clinical outcomes in advanced cancer patients. *NPJ Digit Med* 2018; 1: 27. <https://doi.org/10.1038/s41746-018-0032-6>.
 102. Groarke JM, Richmond J, Mc Sharry J, et al. Acceptability of a mobile health behavior change intervention for cancer survivors with obesity or overweight: nested mixed methods study within a randomized controlled trial. *JMIR mHealth uHealth* 2021; 9: e18288. <https://doi.org/10.2196/18288>.
 103. Gupta A, Stewart T, Bhulani N, et al. Feasibility of wearable physical activity monitors in patients with cancer. *JCO Clin Cancer Inform* 2018; 2: 1–10. <https://doi.org/10.1200/CCI.17.00152>.
 104. Hardcastle SJ, Jimenez-Castuera R, Maxwell-Smith C, et al. Fitbit wear-time and patterns of activity in cancer survivors throughout a physical activity intervention and follow-up: exploratory analysis from a randomised controlled trial. *PloS one* 2020; 15: e0240967. <https://doi.org/10.1371/journal.pone.0240967>.
 105. Hartman SJ, Nelson SH and Weiner LS. Patterns of fitbit use and activity levels throughout a physical activity intervention: exploratory analysis from a randomized controlled trial. *JMIR mHealth uHealth* 2018; 6: e29. <https://doi.org/10.2196/mhealth.8503>.
 106. Helbrich H, Braun M, Hanusch C, et al. Congruence and trajectories of device-measured and self-reported physical activity during therapy for early breast cancer. *Breast Cancer Res Treat* 2021; 188: 351–359. <https://doi.org/10.1007/s10549-021-06195-7>.
 107. Holden T, Hill M, Ward WH, et al. Feasibility of using fitness tracker to assess activity level and toxicities in colorectal cancer (CRC) patients (Pts). *JCO* 2020; 38: 4. DOI: 10.1200/JCO.2020.38.4_suppl.91.
 108. Hoogland AI, Bulls HW, Gonzalez BD, et al. Circadian rhythmicity as a predictor of quality of life in allogeneic hematopoietic cell transplant patients. *J Pain Symptom Manage* 2019; 57: 952–960.e951. <https://doi.org/10.1016/j.jpainsymman.2019.01.015>.
 109. Innominato PF, Komarzynski S, Mohammad-Djafari A, et al. Clinical relevance of the first domomedicine platform securing multidrug chronotherapy delivery in metastatic cancer patients at Home: the inCASA European project. *JMIR* 2016; 18: e305. DOI: 10.2196/jmir.6303.
 110. Ip A, Churnetski MC, Calzada O, et al. The impact of a physical activity intervention can be accurately assessed by smart watches in patients completing autologous stem cell transplantation for lymphoma or multiple myeloma: results of a feasibility study. *Blood* 2018; 132. DOI: 10.1182/blood-2018-99-119757.
 111. Izmailova E, Huang C, Cantor M, et al. Daily step counts to predict hospitalizations during concurrent chemoradiotherapy for solid tumors. *JCO* 2019; 37. DOI: 10.1200/JCO.2019.37.27-suppl.293.
 112. Izmailova ES, Cohen A, Kabarriti R, et al. Daily step counts to predict hospitalizations during chemoradiotherapy for head and neck cancer. *JCO* 2021; 39. DOI: 10.1200/JCO.2021.39.15_suppl.1571.
 113. Jeffery E, Lee YG, McVeigh J, et al. Feasibility of objectively measured physical activity and sedentary behavior in patients with malignant pleural effusion. *Supportive Care Cancer* 2017; 25: 3133–3141. <https://doi.org/10.1007/s00520-017-3721-9>.
 114. Jonker L, Plas M, de Bock GH, et al. Implementing eHealth for postoperative home monitoring of elderly cancer patients: a feasibility study. *Eur J Surg Oncol* 2020; 46: e159. DOI: 10.1016/j.ejso.2019.11.420.
 115. Jonker LT, Plas M, de Bock GH, et al. Remote home monitoring of older surgical cancer patients: perspective on study implementation and feasibility. *Ann Surg Oncol* 2021; 28: 67–78. <https://doi.org/10.1245/s10434-020-08705-1>.
 116. Jovanovic JL, Hughes DC, Baum GP, et al. Accelerometry and self-report in sedentary populations. *Am J Health Behav* 2011; 35: 71–80. DOI: 10.5993/AJHB.35.1.7.
 117. Khetrapal P, Williams N, Tan M, et al. The use of fitness tracker in monitoring functional activity of patients undergoing radical cystectomy for bladder cancer: a feasibility report and analysis as part of the multi-centre randomised iROC trial. *J Urol* 2018; 199: e950. DOI: 10.1016/j.juro.2018.02.2282.
 118. Kim KN, Shah N, Grewal AS, et al. Effect of activity monitoring on quality of life in patients with gastrointestinal cancer undergoing chemoradiation. *JCO* 2021; 39. DOI: 10.1200/JCO.2021.39.15_suppl.e18671.
 119. Komarzynski S, Huang Q, Levi FA, et al. The day after: correlates of patient-reported outcomes with actigraphy-assessed sleep in cancer patients at home (inCASA project). *Sleep* 2019; 42: 146. DOI: 10.1093/sleep/zsz146.
 120. Laccetti AL, Tidwell RS, Sheth NP, et al. Remote patient monitoring using smart phone derived patient reported outcomes and Fitbit data to enable longitudinal predictive modeling in prostate cancer: feasibility results and lessons on platform development. *JCO* 2019; 37. DOI: 10.1200/JCO.2019.37.15_suppl.e18068.
 121. LeBaron V, Alam R, Blackhall L, et al. Using smart health to monitor cancer pain. *Support Care Cancer* 2021; 29: S45. DOI: 10.1007/s00520-021-06285-8.
 122. Liu L, Natarajan L, He F, et al. Actigraphy-based pre-treatment nap time predicts quality of life during chemotherapy in breast cancer patients. *Sleep* 2009; 32: A323.
 123. Low CA, Dey AK, Ferreira D, et al. Using passive smart-phone and wearable sensors to estimation patient-reported stress and symptoms during chemotherapy. *Psychosom Med* 2018; 80: A138. DOI: 10.1097/PSY.0000000000000578.

124. Low CA, Li M, Vega J, et al. Digital biomarkers of symptom burden self-reported by perioperative patients undergoing pancreatic surgery: prospective longitudinal study. *JMIR Cancer* 2021; 7: e27975. <https://doi.org/10.2196/27975>.
125. Lozano-Lozano M, Cantarero-Villanueva I, Martin-Martin L, et al. A mobile system to improve quality of life via energy balance in breast cancer survivors (BENECa mHealth): prospective test-retest quasiexperimental feasibility study. *JMIR mHealth uHealth* 2019; 7: e14136. <https://doi.org/10.2196/14136>.
126. Maddocks M, Byrne A, Johnson CD, et al. Physical activity level as an outcome measure for use in cancer cachexia trials: a feasibility study. *Support Care Cancer* 2010; 18: 1539–1544. DOI: 10.1007/s00520-009-0776-2.
127. Martin CL, Tate DF and Valle CG. Nonadherence to daily self-weighing and activity tracking is associated with weight fluctuations among African American breast cancer survivors. *PLoS one* 2018; 13: e0199751. <https://doi.org/10.1371/journal.pone.0199751>.
128. Miropolsky EM, Scott Baker K, Abbey-Lambertz M, et al. Participant perceptions on a fitbit and Facebook intervention for young adult cancer survivors: a qualitative study. *J Adolesc Young Adult Oncol* 2020; 9: 410–417. <https://doi.org/10.1089/jayao.2019.0072>.
129. Nguyen NH, Hadgraft NT, Moore MM, et al. A qualitative evaluation of breast cancer survivors' acceptance of and preferences for consumer wearable technology activity trackers. *Supportive Care Cancer* 2017; 25: 3375–3384. <https://doi.org/10.1007/s00520-017-3756-y>.
130. Ohri N, Kabarriti R, Bodner WR, et al. Continuous activity monitoring during concurrent chemoradiation therapy. *Int J Radiat Oncol* 2016; 96: E522. DOI: 10.1016/j.ijrobp.2016.06.1937.
131. Otte JL, Payne JK and Carpenter JS. Nighttime variability in wrist actigraphy. *J Nurs Meas* 2011; 19: 105–114.
132. Pavic M, Klaas V, Theile G, et al. Feasibility and usability aspects of continuous remote monitoring of health status in palliative cancer patients using wearables. *Oncology* 2019; 98: 386–395. <https://doi.org/10.1159/000501433>.
133. Pavic M, Klaas V, Theile G, et al. Mobile health technologies for continuous monitoring of cancer patients in palliative care aiming to predict health status deterioration: a feasibility study. *J Palliat Med* 2020; 23: 678–685. <https://doi.org/10.1089/jpm.2019.0342>.
134. Peterson SK, Basen-Engquist K, Demark-Wahnefried W, et al. Feasibility of using home-based mobile sensors for remote patient monitoring in cancer care and prevention. *JCO* 2014; 32. DOI: 10.1200/jco.2014.32.15_suppl.9585.
135. Peterson SK, Garden AS, Shinn EH, et al. Using mobile and sensor technology to identify early dehydration risk in head and neck cancer patients undergoing radiation treatment: impact on symptoms. *JCO* 2018; 36. DOI: 10.1200/JCO.2018.36.15-suppl.6063.
136. Pfister T, Matthews CE, Wang Q, et al. Comparison of two accelerometers for measuring physical activity and sedentary behaviour. *BMJ Open Sport Exerc Med* 2017; 3: e000227. <https://doi.org/10.1136/bmjsem-2017-000227>.
137. Quintiliani LM, Mann DM, Puputti M, et al. Pilot and feasibility test of a mobile health-supported behavioral counseling intervention for weight management among breast cancer survivors. *JMIR Cancer* 2016; 2: e4. DOI: 10.2196/cancer.5305.
138. Rossi A, Frechette L, Miller D, et al. Acceptability and feasibility of a fitbit physical activity monitor for endometrial cancer survivors. *Gynecol Oncol* 2018; 149: 470–475. <https://doi.org/10.1016/j.ygyno.2018.04.560>.
139. Schuler T, Hruby G, Kwong C, et al. Quantitative results from the tracker study: feasibility of real-time activity and weight monitoring during routine care of oncology patients. *J Med Imaging Radiat Oncol* 2019; 63: 100.
140. Sugiyama Y, Naiki T, Tasaki Y, et al. Effectiveness of continuous monitoring by activity tracker of patients undergoing chemotherapy for urothelial carcinoma. *Cancer Treat Res Commun* 2020; 25: 100245. <https://doi.org/10.1016/j.ctarc.2020.100245>.
141. Skipworth RJ, Stene GB, Dahele M, et al. Patient-focused endpoints in advanced cancer: criterion-based validation of accelerometer-based activity monitoring. *Clin Nutr* 2011; 30: 812–821. DOI: 10.1016/j.clnu.2011.05.010.
142. Slade AD, Cardinal JR, Martin CR, et al. Feasibility of wearable activity trackers in cystectomy patients to monitor for postoperative complications. *Curr Urol* 2021; 15: 209–213. DOI: 10.1097/CU9.0000000000000030.
143. Tipps M, Hultman M, Banerji N, et al. Validation of readiband™ actigraph and associated sleep/wake classification algorithms in predicting cancer-related fatigue in high grade glioblastoma. *Neuro-Oncology* 2019; 21: vi132. DOI: 10.1093/neuonc/noz175.551.
144. Torrente M, Franco F, Collazo Lorduy A, et al. Detecting elevated risk of diminished quality of life among lung cancer patients by using wearable devices. *J Thorac Oncol* 2021; 16: S1130–S1131. DOI: 10.1016/j.jtho.2021.08.561.
145. Tramontano A, Scippacercola F and Magliulo M. Estimating quality of life variation using BLE wearable devices on android based architecture. *Int J Radiat Oncol Biol Phys* 2018; 102: e286. DOI: 10.1016/j.ijrobp.2018.07.913.
146. Trinh L, Arbour-Nicitopoulos KP, Sabiston CM, et al. RiseTx: testing the feasibility of a web application for reducing sedentary behavior among prostate cancer survivors receiving androgen deprivation therapy. *Int J Behav Nutr Phys Act* 2018; 15: 49. <https://doi.org/10.1186/s12966-018-0686-0>.
147. Ungar N, Sieverding M, Weidner G, et al. A self-regulation-based intervention to increase physical activity in cancer patients. *Psychol Health Med* 2016; 21: 163–175. <https://doi.org/10.1080/13548506.2015.1081255>.
148. Vallance JK, Boyle T, Courneya KS, et al. Accelerometer-assessed physical activity and sedentary time among colon cancer survivors: associations with psychological health outcomes. *J Cancer Surviv* 2015; 9: 404–411. <https://doi.org/10.1007/s11764-014-0409-8>.
149. Van Blarigan EL, Chan H, Van Loon K, et al. Self-monitoring and reminder text messages to increase physical activity in colorectal cancer survivors (Smart Pace): a pilot randomized controlled trial. *BMC Cancer* 2019; 19: 218. <https://doi.org/10.1186/s12885-019-5427-5>.
150. Verma N, Haji-Abolhassani I, Ganesh S, et al. A novel wearable device for continuous temperature monitoring fever

- detection. *IEEE J Transl Eng Health Med* 2021; 9: 9490248. DOI: 10.1109/JTEHM.2021.3098127.
151. Waliany S, Dieli-Conwright CM, Frankel PH, et al. Validation and feasibility of a caloric expenditure measuring device in women with early-stage breast cancer. *Supportive Care Cancer* 2014; 22: 2329–2336. <https://doi.org/10.1007/s00520-014-2212-5>.
 152. Ward WH, Meeker C, Hill M, et al. Feasibility of using a fitness tracker to assess activity level and toxicity in colorectal cancer patients. *Ann Surg Oncol* 2019; 26: S109. DOI: 10.1245/s10434-019-07174-5.
 153. Wong K, Shen J, Ramezani R, et al. A pilot study of a wearable monitoring system as an adjunct to geriatric assessment in older adults with cancer. *JCO* 2020; 38: 15. DOI: 10.1200/JCO.2020.38.15_suppl.2062.
 154. Wright AA, Raman N, Staples P, et al. The HOPE pilot study: harnessing patient-reported outcomes and biometric data to enhance cancer care. *JCO Clin Cancer Inform* 2018; 2: 1–12. <https://doi.org/10.1200/CCI.17.00149>.
 155. Wu CY, Tibbitts D, Beattie Z, et al. Continuous unobtrusive assessment of meaningful change in older adults with cancer: the pacific aging & cancer study collaborative-PACS collaborative. *JCO* 2021; 39: 1569–1569. DOI: 10.1200/JCO.2021.39.15_suppl.1569.
 156. Zahiri M, Chen KM, Zhou H, et al. Using wearables to screen motor performance deterioration because of cancer and chemotherapy-induced peripheral neuropathy (CIPN) in adults - Toward an early diagnosis of CIPN. *J Geriatr Oncol* 2019; 10: 960–967. DOI: 10.1016/j.jgo.2019.01.010.
-